The Life Sciences Industrial Strategy recommended bringing together regional organisations to create single ‘front-door’ for investment

The launch of the Life Sciences Industrial Strategy recognised the significant contribution that regional clusters make to the UK’s £64bn life science sector.
The Strategy called for existing regional clusters to work together to provide a ‘single front door’ to the UK for research collaboration and investment.

By bringing together cluster organisations, trade bodies and academic consortia, the Government can identify where the UK has globally competitive R&D excellence in life sciences to attract collaboration opportunities and inward investment to the right places.

The launch of the Life Sciences Industrial Strategy follows a year of intense collaboration between a group of life sciences organisations including Northern Health Science Alliance, MedCity, Life Science Hub Wales and the GW4 Alliance.

The group has been working together to better understand how regional clusters can support the delivery of the Life Sciences Industrial Strategy, with support from the Academy of Medical Sciences and Wellcome.

Whilst geographically diverse, this group shares common values and aims:

  • They are typically self-assembled to exploit regional expertise and excellence, and promote improved health and wealth both regionally and nationally.
  • Many act as multi-faceted ‘convening’ bodies which bring together the breadth of the value and supply chain including academia, NHS, Government, industry and membership organisations, to drive the economy.
  • They are supported by formal governance systems, strategies and infrastructure to deliver collaborative research and development at scale.
  • These groups are distinct from membership organisations which exist to represent member needs. Clusters have different finance and operational systems that enables independence, and aim to support regional organisations to drive economic value and health improvement.

This group has welcomed the recommendations of the Life Science Industrial Strategy and has called for the UK Government to continue to work closely with its members and the Academy of Medical Sciences to deliver a sector deal that will ensure that the sector remains at the leading edge of life science research and health innovation globally.

Commenting on the report:
Sarah Haywood, CEO of MedCity noted: “The strategy recognises the strength of the Golden Triangle of Cambridge-London-Oxford within the life sciences sector.  Nevertheless, we cannot take for granted what we have.  There is a continuing need to support joining up across academia, industry large and small and the NHS.  The strategy identifies the role that cluster organisations can play in supporting the places that drive the UK’s life sciences sector.  Working together we can provide a front door to the UK’s capability and make it easier for different groups to find and work with each other.”